Aflibercept vs Brolucizumab-Dbll

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
NEI VFQ-25 Total 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4
absolute change · score
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 5 more results
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 6.3 Ranibizumab score @ 52wk2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.9 vs 6.3 Ranibizumab score @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.1 vs 6.3 Ranibizumab score @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14 vs 3.9 PDT Letters correctly read @ 28wk
NCT01482910 · Phase 3 · registry result, not featured evidence
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 8.1 ETDRS Letters @ 52wk
absolute change · ETDRS Letters
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 ETDRS Letters @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
CST Change Microns -248.8 um @ 52wk
absolute change · um
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence
show 1 more result
-164.8 um @ 52wk
NCT03117634 · Phase 4 · registry result, not featured evidence
Complete Polyp Regression 53.8% (n=39) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 1 more result
38.5% (n=13) @ 52wk*
NCT03117634 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
BCVA Letters 0.3 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.33 score @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence
CST Change Microns 0.08 ratio @ 24wk
ratio to baseline · ratio
No placebo or comparator arm
NCT03022292 · Phase 4 · registry result, not featured evidence
show 1 more result
0.07 ratio @ 52wk
NCT03022292 · Phase 4 · registry result, not featured evidence

+ 63 further endpoints in the CSV export.

Available safety results

Aflibercept

Dropout rate
3.6%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
4.9%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%
NCT03022292 · Phase 4 · registry result, not featured evidence
6.1%
NCT02689518 · Phase 4 · registry result, not featured evidence
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
100%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
8.7%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
12.7%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
6.3%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.2%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
6.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
5%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
21.1%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
23.6%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
Discontinued due to AEs
1%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
—
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
20%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
2.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
3.2%Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—
NCT01950741 · Phase 4 · registry result, not featured evidence
—2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
2.6%Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
—PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
3.2%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
Serious AEs
23%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 44 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0%Fixed Group
NCT03117634 · Phase 4 · registry result, not featured evidence
7.7%Personalised Group
NCT03117634 · Phase 4 · registry result, not featured evidence
3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
—
NCT02689518 · Phase 4 · registry result, not featured evidence
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
26.7%Aflibercept (Non-randomized)
NCT02120950 · Phase 4 · registry result, not featured evidence
15.5%Aflibercept + Active PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
17.2%Aflibercept + Sham PDT
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
—Aflibercept + Sham Photodynamic Th
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
2.1%
NCT01950741 · Phase 4 · registry result, not featured evidence
20%2.0 mg
NCT01543568 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
—Aflibercept Injection (EYLEA, VEGF
NCT01482910 · Phase 3 · registry result, not featured evidence
2.3%Aflibercept Injection, From Week 2
NCT01482910 · Phase 3 · registry result, not featured evidence
5.7%Aflibercept Injection, up to Week
NCT01482910 · Phase 3 · registry result, not featured evidence
4.2%PDT Then Aflibercept Injection, Fr
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
10.3%4.0 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
10%0.5 mg iSONEP
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
15.8%Monotherapy
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
45.9%2mg
NCT00527423 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
Most frequent reported AEs
2.0mg Q4
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 39 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
drop in visual acuity 7.7%
punctate epithelial erosion 7.7%
raised blood pressure 7.7%
NCT03117634 · Phase 4 · registry result, not featured evidence
drop in vision due to cataract 5.1%
drop in visual acuity 5.1%
peri-orbital oedema (extra-ocular) 2.6%
NCT03117634 · Phase 4 · registry result, not featured evidence
myelodysplastic syndrome 3.8%
pneumonia 3.8%
NCT03022292 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
hypertension 13.3%
depression 6.7%
ocular hypertension 6.7%
NCT02120950 · Phase 4 · registry result, not featured evidence
viral upper respiratory tract infection 11.2%
hypertension 8.1%
dry eye 6.8%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
viral upper respiratory tract infection 15.9%
conjunctival haemorrhage 6.4%
vitreous floaters 5.7%
NCT02120950 · Phase 4 · registry result, not featured evidence · combination
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
conjunctival hemorrhage 8.5%
NCT01950741 · Phase 4 · registry result, not featured evidence
2.0 mg
cataract progression 6.7%
geographic atrophy progression 6.7%
NCT01543568 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
conjunctival haemorrhage 6%
macular fibrosis 2.8%
retinal pigment epitheliopathy 2.8%
NCT01482910 · Phase 3 · registry result, not featured evidence
macular fibrosis 11.8%
visual acuity reduced 7%
conjunctival haemorrhage 6.1%
NCT01482910 · Phase 3 · registry result, not featured evidence
visual acuity reduced 7%
conjunctival haemorrhage 5.6%
intraocular pressure increased 1.4%
NCT01482910 · Phase 3 · registry result, not featured evidence · combination
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
4.0 mg iSONEP
conjunctival haemorrhage 53.8%
intraocular pressure increased 28.2%
vitreous floaters 20.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
0.5 mg iSONEP
conjunctival haemorrhage 60%
activated partial thromboplastin time prolonged 12.5%
vitreous floaters 12.5%
NCT01414153 · Phase 2 · registry result, not featured evidence · combination
conjunctival haemorrhage 34.2%
retinal haemorrhage 28.9%
arthralgia 7.9%
NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy
2mg
fall 18.5%
hypertension 16.6%
nasopharyngitis 16.6%
NCT00527423 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence

Wet Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Wet Age-Related Macular Degenerationfusion protein
Reliable signal

NCT00509795 · Phase 3 · completed

The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.

Next expected readout: June 2027 · NCT04932980 (registry estimate)

Reported efficacy

Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)

Result source: NCT00509795

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Wet Age-Related Macular Degenerationantibody fragment (scFv)
Reliable signal

NCT02307682 · Phase 3 · completed

Randomized, double-blind, active-controlled Phase 3 trial in 1,078 treated patients with neovascular AMD; the primary endpoint was change in best-corrected visual acuity at 48 weeks. Both brolucizumab doses met the prespecified non-inferiority margin versus aflibercept (3 mg difference -0.6 letters, 95% CI -2.5 to 1.3; 6 mg difference -0.2 letters, 95% CI -2.1 to 1.8; margin 4 letters), providing strong comparative evidence that brolucizumab is not worse than aflibercept on this functional endpoint.

No aligned efficacy figure on record for this race.

Results for Wet Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Wet Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Maintained Vision 95.1% (n=285) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.1% (n=265) vs 94.4% (n=269) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
95.9% (n=270) vs 94.4% (n=269) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 10.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q4
absolute change · letters read
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
7.9 vs 8.1 Ranibizumab letters read @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.9 vs 8.1 Ranibizumab letters read @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 37.5% (n=304) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q4
absolute value · percentage points
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
30.6% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.9% (n=301) vs 30.9% (n=304) Ranibizumab @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
NEI VFQ-25 Total 6.7 vs 4.9 Ranibizumab score @ 52wk2.0mg Q4
absolute change · score
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 5 more results
5.1 vs 4.9 Ranibizumab score @ 52wk2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 6.3 Ranibizumab score @ 52wk2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.9 vs 6.3 Ranibizumab score @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
4.5 vs 4.9 Ranibizumab score @ 52wk0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.1 vs 6.3 Ranibizumab score @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintenance 95.62% (n=274) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
95.56% (n=270) vs 94.42% (n=269) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
96.27% (n=268) vs 94.42% (n=269) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters 7.6 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q4
absolute change · Letters correctly read
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 6 more results
8.9 vs 9.4 Ranibizumab Letters correctly read @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
5.4 vs 5.2 REGN910-3 Letters correctly read @ 12wk2 mg
NCT02713204 · Phase 2 · registry result, not featured evidence
6.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
4.2 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 2 mg Q12
NCT02713204 · Phase 2 · registry result, not featured evidence
2.9 vs 5.9 REGN910-3 Letters correctly read @ 36wk2 mg Q4 to 6 mg:2 mg Q8
NCT02713204 · Phase 2 · registry result, not featured evidence
9.7 vs 9.4 Ranibizumab Letters correctly read @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 29.45% (n=309) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q4
responder rate · % of participants
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
31.37% (n=306) vs 34.02% (n=291) Ranibizumab @ 52wk2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
34.8% (n=296) vs 34.02% (n=291) Ranibizumab @ 52wk0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Change Letters -2.1 Letters correctly read @ 104wk2 mg intravitreal
absolute change · Letters correctly read
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.4 Letters correctly read @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Loss Less Than 15 Letters 93.4% (n=106) @ 104wk2 mg intravitreal
responder rate · % of participants
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 3 more results
96.2% (n=104) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=106) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
100% (n=104) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Change Letters 7.8 Letters @ 52wk2 mg intravitreal
absolute change · Letters
No placebo or comparator arm
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
10.2 Letters @ 52wk2 mg intravitreal
From baseline to Week 52
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Change Letters 4.3 Letters @ 104wk2 mg intravitreal
absolute change · Letters
No placebo or comparator arm
From baseline to Week 104
NCT02581891 · Phase 4 · registry result, not featured evidence
show 1 more result
7.9 Letters @ 104wk2 mg intravitreal
From baseline to Week 104
NCT02581891 · Phase 4 · registry result, not featured evidence
BCVA Gain 15 Letters 19.8% (n=106) @ 52wk2 mg intravitreal
responder rate · % of participants
No placebo or comparator arm
NCT02581891 · Phase 4 · registry result, not featured evidence
show 12 more results
27.9% (n=104) @ 52wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
18.9% (n=106) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
22.1% (n=104) @ 104wk2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.8% (n=31) @ 12wk2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
16.1% (n=31) @ 12wk2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
18.8% (n=32) @ 12wk0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
21.9% (n=32) @ 12wk0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
9.7% (n=31) @ 12wk4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
32.5% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
30.9% (n=123) @ 52wk
NCT02305238 · Phase 4 · registry result, not featured evidence
25.8% (n=151) @ 52wk
NCT01722045 · Phase 4 · registry result, not featured evidence
22.5% (n=151) @ 100wk
NCT01722045 · Phase 4 · registry result, not featured evidence

+ 38 further endpoints in the CSV export.

Available safety results

Aflibercept

Dropout rate
3.6%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
8.9%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
10.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
9.3%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
11.9%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
14%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
12.9%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
15.4%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
18.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
8.3%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
11.3%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0.9%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
95%
NCT00964795 · Phase 3 · registry result, not featured evidence
9.7%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
9.4%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
3.8%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
22.5%
NCT01773954 · Phase na · registry result, not featured evidence
Discontinued due to AEs
1%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
1.3%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.6%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
1.9%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.6%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
3%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
4.4%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
3.2%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
1.6%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
5.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.2%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
2.4%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
0%Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
3.7%
NCT00964795 · Phase 3 · registry result, not featured evidence
—RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
—Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
1.9%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—
NCT01773954 · Phase na · registry result, not featured evidence
Serious AEs
23%2.0mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 26 more results
29.7%2.0mg Q8
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
28.9%0.5mg Q4
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.2%2 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
26.4%2 mg Q8
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
24.2%0.5 mg Q4
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
21.5%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
25.7%2 mg intravitreal
NCT02581891 · Phase 4 · registry result, not featured evidence
15.3%2 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
16.3%4 Weeks Adjustment
NCT02305238 · Phase 4 · registry result, not featured evidence
29.2%
NCT01722045 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
13.7%2 mg every 8 weeks
NCT02540954 · Phase 3 · registry result, not featured evidence
15.6%Aflibercept Extended Dosing
NCT02540954 · Phase 3 · registry result, not featured evidence
6.5%6 mg
NCT03386474 · Phase 3 · registry result, not featured evidence
—Brolucizumab - Overall Extension S
NCT03386474 · Phase 3 · registry result, not featured evidence
6.5%Brolucizumab Overall Last 6 Months
NCT03386474 · Phase 3 · registry result, not featured evidence
32.5%
NCT00964795 · Phase 3 · registry result, not featured evidence
6.9%RBM-007 + Aflibercept
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
7.1%Sham + RBM-007
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
13.2%
NCT04126317 · Phase 2 · registry result, not featured evidence
—2.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—2.0 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
—0.5 mg q4
NCT00320788 · Phase 2 · registry result, not featured evidence
—4.0 mg q12
NCT00320788 · Phase 2 · registry result, not featured evidence
5%
NCT01773954 · Phase na · registry result, not featured evidence
Most frequent reported AEs
2.0mg Q4
vitreous floaters 16.1%
nasopharyngitis 15.1%
eye disorders pain 12.8%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 24 more results
2.0mg Q8
nasopharyngitis 12.9%
hypertension 10.9%
eye disorders pain 10.2%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5mg Q4
nasopharyngitis 13.5%
retinal haemorrhage 11.8%
eye disorders pain 11.5%
NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q4
retinal haemorrhage 27.2%
visual acuity reduced 14.2%
hypertension 13.3%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg Q8
retinal haemorrhage 26.7%
visual acuity reduced 19.5%
macular degeneration 16.6%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
0.5 mg Q4
retinal haemorrhage 23.6%
visual acuity reduced 18.5%
conjunctival haemorrhage 15.5%
NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2 mg intravitreal
visual acuity reduced 15.6%
conjunctival haemorrhage 14.8%
nasopharyngitis 13.3%
NCT02581891 · Phase 4 · registry result, not featured evidence
2 mg intravitreal
conjunctival haemorrhage 13.2%
nasopharyngitis 12.5%
visual acuity reduced 12.5%
NCT02581891 · Phase 4 · registry result, not featured evidence
nasopharyngitis 21%
cataract 4%
conjunctival haemorrhage 3.2%
NCT02305238 · Phase 4 · registry result, not featured evidence
nasopharyngitis 16.3%
cataract 8.1%
conjunctival haemorrhage 6.5%
NCT02305238 · Phase 4 · registry result, not featured evidence
neovascular age-related macular degeneration 13%
hypertension 8.4%
conjunctival haemorrhage 7.8%
NCT01722045 · Phase 4 · registry result, not featured evidence
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg every 8 weeks
cataract 11.3%
subretinal fluid 8.3%
nasopharyngitis 7.1%
NCT02540954 · Phase 3 · registry result, not featured evidence
cataract 10.2%
subretinal fluid 8.4%
visual acuity reduced 8.4%
NCT02540954 · Phase 3 · registry result, not featured evidence
6 mg
nasopharyngitis 4.7%
urinary tract infection 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
urinary tract infection 5.6%
nasopharyngitis 3.7%
neovascular age-related macular degeneration - fellow eye 1.9%
NCT03386474 · Phase 3 · registry result, not featured evidence
retinal haemorrhage 12.1%
retinal haemorrhage 10.5%
age-related macular degeneration 9.3%
NCT00964795 · Phase 3 · registry result, not featured evidence
eye disorders 51.7%
conjunctival haemorrhage 20.7%
eye irritation 6.9%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
eye disorders 46.4%
conjunctival haemorrhage 17.9%
dry eye 14.3%
NCT04200248 · Phase 2 · registry result, not featured evidence · combination
neovascular age-related macular degeneration fellow eye 7.5%
vitreous detachment study eye 7.5%
conjunctival haemorrhage fellow eye 5.7%
NCT04126317 · Phase 2 · registry result, not featured evidence
2.0 mg q12
upper respiratory tract infection 19.4%
blepharitis 9.7%
retinal haemorrhage 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence
2.0 mg q4
urinary tract infection 19.4%
eye pain 12.9%
visual acuity reduced 12.9%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q12
refraction disorder 12.5%
headache 9.4%
intraocular pressure increased 9.4%
NCT00320788 · Phase 2 · registry result, not featured evidence
0.5 mg q4
hypertension 18.8%
bronchitis 15.6%
constipation 15.6%
NCT00320788 · Phase 2 · registry result, not featured evidence
4.0 mg q12
vitreous detachment 12.9%
bronchitis 9.7%
eye pain 9.7%
NCT00320788 · Phase 2 · registry result, not featured evidence

Diabetic Macular Edema

Shared mechanism: VEGF-A · full Diabetic Macular Edema pipeline

Aflibercept · Eylea

Marketed by Regeneron Pharmaceuticals and partners

Approved in Diabetic Macular Edemafusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT02645266 (registry estimate)

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Diabetic Macular Edemaantibody fragment (scFv)
Partial signal

NCT04955171 · Phase 3 · status unknown

Randomized, active-comparator trial testing brolucizumab head-to-head against an established anti-VEGF therapy for diabetic macular edema, though masking was limited to participants only and the trial is relatively small. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Diabetic Macular Edema

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: no structured comparison results are available for Diabetic Macular Edema.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aflibercept

BCVA Change Letters 10.5 vs 1.2 Macular Laser Photocoagulation Letters correctly read @ 52wk2 mg every 4 weeks
absolute change · Letters correctly read
NCT01331681 · Phase 3
show 3 more results
10.7 vs 1.2 Macular Laser Photocoagulation Letters correctly read @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
13.7 vs -0.2 Macular Laser Photocoagulation Letters correctly read @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
12.8 vs -0.2 Macular Laser Photocoagulation Letters correctly read @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
BCVA Gain 10 Letters 54.4% (n=136) vs 25.8% (n=132) Macular Laser Photocoagulation @ 52wk2 mg every 4 weeks
responder rate · % of participants
NCT01331681 · Phase 3
show 3 more results
53.3% (n=135) vs 25.8% (n=132) Macular Laser Photocoagulation @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
70.9% (n=127) vs 23.4% (n=124) Macular Laser Photocoagulation @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
62.7% (n=126) vs 23.4% (n=124) Macular Laser Photocoagulation @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
BCVA Gain 15 Letters 32.4% (n=136) vs 9.1% (n=132) Macular Laser Photocoagulation @ 52wk2 mg every 4 weeks
responder rate · % of participants
NCT01331681 · Phase 3
show 3 more results
33.3% (n=135) vs 9.1% (n=132) Macular Laser Photocoagulation @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
43.3% (n=127) vs 12.1% (n=124) Macular Laser Photocoagulation @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
36.5% (n=126) vs 12.1% (n=124) Macular Laser Photocoagulation @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
ETDRS DRSS 2-step Improvement 33.3% (n=81) vs 7.5% (n=80) Macular Laser Photocoagulation @ 52wk2 mg every 4 weeks
responder rate · % of participants
NCT01331681 · Phase 3
show 1 more result
27.7% (n=83) vs 7.5% (n=80) Macular Laser Photocoagulation @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
CST Change Microns -195 vs -66.2 Macular Laser Photocoagulation micrometer @ 52wk2 mg every 4 weeks
absolute change · micrometer
NCT01331681 · Phase 3
show 3 more results
-192.4 vs -66.2 Macular Laser Photocoagulation micrometer @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
-238.7 vs -109.3 Macular Laser Photocoagulation micrometer @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
-234.7 vs -109.3 Macular Laser Photocoagulation micrometer @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
NEI VFQ-25 Near Activities 5.73 vs 3.54 Macular Laser Photocoagulation score @ 52wk2 mg every 4 weeks
absolute change · score
NCT01331681 · Phase 3
show 3 more results
5.29 vs 3.54 Macular Laser Photocoagulation score @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
6.65 vs 0.04 Macular Laser Photocoagulation score @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
7.28 vs 0.04 Macular Laser Photocoagulation score @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
NEI VFQ-25 Distance Activities 0.94 vs 2.26 Macular Laser Photocoagulation score @ 52wk2 mg every 4 weeks
absolute change · score
NCT01331681 · Phase 3
show 3 more results
5.32 vs 2.26 Macular Laser Photocoagulation score @ 52wk2 mg every 8 weeks
NCT01331681 · Phase 3
3.93 vs 0.04 Macular Laser Photocoagulation score @ 52wk2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
10.25 vs 0.04 Macular Laser Photocoagulation score @ 52wk2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
BCVA Change Letters 74 letters @ 52wk
absolute change · letters
No placebo or comparator arm
NCT02559180 · Phase 4 · registry result, not featured evidence
show 3 more results
71.5 letters @ 26wk
NCT02559180 · Phase 4 · registry result, not featured evidence
74 letters @ 52wk
NCT02559180 · Phase 4 · registry result, not featured evidence
75 letters @ 104wk
NCT02559180 · Phase 4 · registry result, not featured evidence
CFT Change Microns 287.2 m @ 52wk
absolute change · m
No placebo or comparator arm
NCT02559180 · Phase 4 · registry result, not featured evidence
Panretinal Leakage Index -3.14% (n=29) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT02503540 · Phase 4 · registry result, not featured evidence
Total Leakage Index 0.47% (n=29) @ 26wk
absolute change · percentage points
No placebo or comparator arm
NCT02503540 · Phase 4 · registry result, not featured evidence
Panretinal Ischemic Index 3.2% (n=28) @ 52wk
absolute change · percentage points
No placebo or comparator arm
NCT02503540 · Phase 4 · registry result, not featured evidence
show 1 more result
0.67% (n=28) @ 26wk
NCT02503540 · Phase 4 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

Available safety results

Aflibercept

Dropout rate
25.7%2 mg every 4 weeks
NCT01331681 · Phase 3
show 9 more results
25.2%2 mg every 8 weeks
NCT01331681 · Phase 3
20%
NCT02559180 · Phase 4 · registry result, not featured evidence
9.7%
NCT02503540 · Phase 4 · registry result, not featured evidence
0%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
10.4%2 mg extended
NCT02818998 · Phase 3 · registry result, not featured evidence
11.6%2 mg fixed
NCT02818998 · Phase 3 · registry result, not featured evidence
11.7%2 mg PRN
NCT02818998 · Phase 3 · registry result, not featured evidence
3.9%2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
8.7%2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
7.4%2 mg every 4 weeks
NCT01331681 · Phase 3
show 9 more results
9.6%2 mg every 8 weeks
NCT01331681 · Phase 3
—
NCT02559180 · Phase 4 · registry result, not featured evidence
—
NCT02503540 · Phase 4 · registry result, not featured evidence
—8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
1.3%2 mg extended
NCT02818998 · Phase 3 · registry result, not featured evidence
1.9%2 mg fixed
NCT02818998 · Phase 3 · registry result, not featured evidence
0.6%2 mg PRN
NCT02818998 · Phase 3 · registry result, not featured evidence
3.1%2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
3.9%2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
Serious AEs
—2 mg every 4 weeks
NCT01331681 · Phase 3
show 9 more results
—2 mg every 8 weeks
NCT01331681 · Phase 3
20%
NCT02559180 · Phase 4 · registry result, not featured evidence
9.7%
NCT02503540 · Phase 4 · registry result, not featured evidence
5.7%8 mg
NCT05989126 · Phase 3 · registry result, not featured evidence
24.7%2 mg extended
NCT02818998 · Phase 3 · registry result, not featured evidence
22.6%2 mg fixed
NCT02818998 · Phase 3 · registry result, not featured evidence
24%2 mg PRN
NCT02818998 · Phase 3 · registry result, not featured evidence
15%2Q4
NCT01783886 · Phase 3 · registry result, not featured evidence
17.3%2Q8
NCT01783886 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
2 mg every 4 weeks
conjunctival haemorrhage 31.6%
nasopharyngitis 27.9%
diabetic retinal oedema 24.3%
NCT01331681 · Phase 3
show 7 more results
2 mg every 8 weeks
conjunctival haemorrhage 28.9%
nasopharyngitis 28.9%
visual acuity reduced 24.4%
NCT01331681 · Phase 3
8 mg
hypertension 5.7%
NCT05989126 · Phase 3 · registry result, not featured evidence
2 mg extended
cataract 18.8%
visual acuity reduced 14.3%
diabetic retinopathy 9.1%
NCT02818998 · Phase 3 · registry result, not featured evidence
2 mg fixed
cataract 17.4%
visual acuity reduced 16.1%
diabetes mellitus 15.5%
NCT02818998 · Phase 3 · registry result, not featured evidence
2 mg PRN
cataract 15.6%
visual acuity reduced 14.3%
diabetic retinopathy 11.7%
NCT02818998 · Phase 3 · registry result, not featured evidence
2Q4
conjunctival haemorrhage 14.2%
diabetic retinal oedema 13.4%
retinal haemorrhage 11%
NCT01783886 · Phase 3 · registry result, not featured evidence
2Q8
retinal haemorrhage 13.4%
hypertension 11.8%
visual acuity reduced 11%
NCT01783886 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Brolucizumab-Dbll's landscape